Neuraxis (NRXS) Net Equity Issued and Repurchased (2023 - 2026)

Neuraxis (NRXS) posted Net Equity Issued and Repurchased of $2.3 million for Q1 2026, down 15.25% sequentially from $2.7 million in Q4 2025.

Neuraxis (NRXS) Net Equity Issued and Repurchased (2023 - 2026) Analysis & Trends

Neuraxis has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $2.3 million in Q1 2026.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (changed N/A YoY) and the FY2025 annual result came in at $7.7 million, changed N/A from the prior year.
Net Equity Issued and Repurchased retreated to $2.3 million in Q1 2026 per NRXS's latest filing, from $2.7 million in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $2.7 million in Q4 2025 and troughed at -$617185.0 in Q4 2023.
A 3-year average of $1.5 million and a median of $2.3 million in 2026 frame the typical range for Net Equity Issued and Repurchased.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Neuraxis	74.54 Mn	66.21 Mn	-	-

Download Data